Category Archives: Stem Cells

Wilmington, Delaware, United States, Transparency Market Research Inc.: Stem cells are bodys raw materials or cells from which all other cells with specialized functions are generated. These cells can be guided to become specific cells that regenerate and repair diseased or damaged tissues in patients suffering from various diseases.

Read Report Overview - https://www.transparencymarketresearch.com/stem-cell-and-regenerative-therapy-market.html

This stem cell therapy is called regenerative medicine or regenerative therapy to treat several diseases. Stem cell and regenerative therapy promotes the repair response of diseased, injured, or dysfunctional tissue using stem cells or derivatives of stem cells.

Stem cell therapies can be used to treat patients with Parkinson's disease, amyotrophic lateral sclerosis, diabetes type 1, Alzheimer's disease, heart disease, stroke, burns, cancer, and osteoarthritis

In advanced therapies, stem cells are used to replace damaged cells and serve as a replacement method for the donor's immune system to fight several types of blood-related diseases and cancer

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75161

Key Drivers and Restraints of Global Stem Cell and Regenerative Therapy Market

Unclear Regulatory Guidelines Hampers Global Market

Get COVID-19 Analysis on Stem Cell and Regenerative Therapy Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75161

Cell Therapy Segment to Dominate Global Market

Oncology to be Highly Promising Segment

Hospitals to be Major End-user Segment

Make an Enquiry Before Buying - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=75161

North America to Lead Global Stem Cell and Regenerative Therapy Market

Key Manufacturers Operating in Global Stem Cell and Regenerative Therapy Market

Key manufacturers operating in the global market are:

More Trending Reports by Transparency Market Research

Clinical Laboratory Services Market: https://www.transparencymarketresearch.com/clinical-laboratory-services-market.html

Nasopharyngeal Swabs Market: https://www.transparencymarketresearch.com/nasopharyngeal-swabs-market.html

Blood Purification Equipment Market: https://www.transparencymarketresearch.com/blood-purification-equipment-market.html

Epileptic Seizures Treatment Market: https://www.transparencymarketresearch.com/epileptic-seizures-treatment-market.html

Positron Emission Tomography [PET] Scanners Market: https://www.transparencymarketresearch.com/positron-emission-tomography-pet-scanners-market.html

Ethylene-vinyl Acetate [EVA] Infusion Bags Market: https://www.transparencymarketresearch.com/ethylenevinyl-acetate-eva-infusion-bags-market.html

Bone Graft Substitutes Market: https://www.transparencymarketresearch.com/bone-graft-substitutes-market.html

Corporate Wellness Market: https://www.transparencymarketresearch.com/asia-pacific-corporate-wellness-market.html

About Us

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update - https://www.youtube.com/channel/UC8e-z-g23-TdDMuODiL8BKQ

Contact

Rohit BhiseyTransparency Market Research Inc.CORPORATE HEADQUARTER DOWNTOWN,1000 N. West Street,Suite 1200, Wilmington, Delaware 19801 USATel: +1-518-618-1030USA Canada Toll Free: 866-552-3453Website: https://www.transparencymarketresearch.comBlog: https://tmrblog.comEmail: sales@transparencymarketresearch.com

See the original post:
Stem Cell and Regenerative Therapy Market: Rise in Prevalence of Different Chronic Diseases across the World to Drive the Market - BioSpace

MAGNETIC bandages may soon be used to repair worn joints and mend broken bones.

Combining the dressings with an injection of stem cells helps cartilage and bone to regrow, researchers found.

1

The method, in which patients would recover at home, could spell the end of hip and knee replacement ops.

The NHS does about 100,000 of each every year, as well as spending 2billion on treating 850,000 broken bones.

The technique sees tiny magnetic particles attached to stem cells which are able to turn into bone and cartilage.

They are injected before being guided to the damaged areas and activated by the magnetic bandage.

In tests on sheep, the treatment sped up bone repair. Human trials are planned.

Prof Alicia El Haj, of Birmingham University, said the method worked better than existing treatments and would be quicker, cheaper and much less painful.

She said: You could have it in a GP clinic.

The breakthrough is being presented at the Royal Society summer science exhibition.

Read this article:
Magnetic bandages with stem cells to be used to repair worn joints and mend broken bones... - The Sun

CAR T cells (CTC) which can be manufactured in a single day have been shown to be effective and with an acceptable safety profile, for the treatment of patients with relapsed or refractory B cell acute lymphoblastic leukaemia according to a first-in-human clinical study by a group of Chinese researchers.

Chimeric antigen receptor-engineered T cells (CAR T cells) represents a novel yet safe and effective therapy for B-cell acute lymphoblastic leukaemiapatients relapsing after an allotransplant. In CTC therapy, the patients own T cells are genetically engineered and then re-infused in an effort to eliminate their tumour cells.The T cells contain an extracellular ligand binding domain which is able to recognise antigens displayed on the surface of tumour cells (normally CD19). Moreover, it appears to be an effective form of therapy with one study from 2018 demonstrating complete remission in 83% of patients with relapsed B-cell acute lymphoblastic leukaemia. Nevertheless, as more clinicals have been undertaken, it has become evident that 30-60% patients relapse after treatment, probably due to persistence of CAR T-cells and escape or down-regulation of CD19 antigen. A further problem is that the T-cell engineering process can take 9 to 14 days and up to four weeks before infusion back into the patient.

For the present study, the Chinese team developed a type of CAR T cells that were manufactured using a novel process completed in 24 hours. The final product CTC product, GC007F was tested in patients with relapsed or refractory B cell acute lymphoblastic leukaemia and for comparative purposes, the researchers also manufactured CTCs by conventional methods.

CAR T cells and patient outcomes

A total of 21 patients with CD19+ relapsed or refractory B cell acute lymphoblastic leukaemia were enrolled and given a single infusion of GC007F cells although only 18 were included in the final analysis after the others withdrew due to adverse effects. The median peak of CAR T cells was on day 10 and the median persistence was 56 days. The GC007F cells also showed better proliferation and tumour killing than conventional CTCs.

After 28 days, all patients had achieved complete remission (CR), with 17 achieving CR and maintaining minimal residual disease negative, MRD (i.e., no disease was detected after treatment) after 3 months. Additionally, at 6 months, 16 patients maintained CR with 14 maintaining MRD negative and the longest duration at the time of writing was 29 months without the need for transplant.

In terms of safety, 95.2% (n = 20) of patients experienced cytokine release syndrome (a recognised adverse effect) and which was greater than grade 3 (i.e., severe) in 52.4% (11) of patients. Neurotoxicity developed in 6 patients and was greater than grade 3 severity in 3 patients.

Overall, eight patients underwent allogeneic haematopoietic stem cell transplantation after GC007F treatment.

The authors concluded that these preliminary data suggested that their next day GC007F cells appeared to be effective and with a manageable toxicity profile.

CitationZhang C et al. Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia Blood Cancer J 2022

Visit link:
Next day CAR T cells effective and have acceptable safety in acute lymphoblastic leukaemia - Hospital Healthcare Europe

The3D cell culture marketrevenues surpassed US$ 778 million in 2018,as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

Request Sample Copy of Report:https://www.futuremarketinsights.com/reports/sample/rep-gb-2843

The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold-free 3D cell culture. Owing to the significant adoption of scaffold-based 3D cell culture, the study finds that this technique garnered over 81% of the global market revenues.

Scaffold-based 3D cell culture techniques deliver researchers with additional functional operations in terms of material natural or synthetic and different mechanical properties.

The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.

According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.

While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering, and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years, says FMI.

Leading Manufacturers in the 3D Cell Culture Market:

Competitive Landscape of the Global 3D Cell Culture Market

The competition section of the 3D cell culture market represents the profiles of the key players operating in the 3D cell culture market based on the products they offer and the total revenue of the companies. Some of the key players featured in this report include Thermo Fisher Scientific Inc., Merck KGaA, Becton, Dickinson and Company, Lonza, and Corning Incorporated.

The key manufacturers of 3D cell culture offer a wide range of products. Thermo Fisher Scientific, Inc. has developed a joint platform for advancing research in precision medicine.

Corning, one of the major leaders in 3D cell culture market, manufactures cell culture products, which include consumables (such as plastic vessels, specialty surfaces, cell culture media, and serum), as well as general labware and equipment, which are used for advanced cell culture research.

Download PDF Brochure @https://www.futuremarketinsights.com/reports/brochure/rep-gb-2843

Application of 3D Cell Culture in Cancer Research Prominent

The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.

2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.

Stem cell technology is another lucrative field for3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.

Revenues in North America Continue to Surge

North America continued to spearhead the revenues of 3D cell culture market during the historical period and the status-quo is likely to continue in the future. In 2018, North America accounted for over two-fifths of the global 3D cell culture market revenues. The study estimates that regional revenues are expected to grow at 8% in 2019 over 2018.

Funding in research and development, especially in cancer research remains higher in the United States as compared to other developed countries. Europe also presents significant funding in R&D activities. The FMI study finds that over one-fourth of the 3D cell culture market revenues were accounted for the Europe region in 2018, of which a bulk of revenues come from Western European countries such as Germany, the UK, France, Italy and Spain.

Key SegmentBased on product type

Based on application

Based on end user

Explore Other Reports Links From Healthcare Market:

https://drujrake.mn.co/posts/24898121

https://tennispassion.mn.co/posts/24898141

https://skin-care-junkies.mn.co/posts/24898157

About FMI:

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 9-years.

Contact Us:Future Market Insights,Unit No: 1602-006,Jumeirah Bay 2,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers,Dubai,United Arab EmiratesFor Sales Enquiries:sales@futuremarketinsights.comWebsite:https://www.futuremarketinsights.comLinkedIn|Twitter|Blogs

Read the original post:
3D Cell Culture Market to attain a valuation of US$ 2.67 Billion by 2031 - PharmiWeb.com

Samer A. Srour, MB, ChB, MS, assistant professor in the Department of Stem Cell Transplantation and Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, spoke with CancerNetwork at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about results observed in a phase 2 (NCT01729091) which assessed the use of umbilical cord bloodderived natural killer cells with elotuzumab (Empliciti), lenalidomide (Revlimid), and high-dose melphalan (Evomela) followed by autologous stem cell transplantation for patients with high-risk multiple myeloma.

Srour noted a progression-free survival (PFS) rate of 83% and an overall survival (OS) rate of 97% among patients who were treated with the regimen.

This expansion phase 2 cohort was included in the final platform of elotuzumab, lenalidomide, and the cord bloodderived expanded [natural killer] cells. We started this in early 2018, and we accrued the last patient in early 2021, so over 2 years. Despite COVID, we were able to accrue very well on this study. Now we have mature data after an immediate follow-up of 26 months for these 30 patients who all have high-risk multiple myeloma. Historically, we know the median survival is short, [about] less than 3 to 5 years, and with all the new treatments in myeloma, we were not able to overcome much of the resistance in [many] of the high-risk patients.

Thirty patients were included in this study over a 2 plus year period. The primary end point was best response rate on day 100 after transplant, [including] VGPR, very good partial response or better, and MRD [minimal residual disease] negativity at day 100 after transplant. We gave this regimen in the context of the transplant. Patients took elotuzumab, lenalidomide, and high-dose melphalan [followed by] the [natural killer] cells. After that, we gave them back their autologous stem cells, and then they were engrafted as with any other [patients with] myeloma. They engrafted on time within 10 to 11 days from the transplant. We looked at the best response at 3 months after transplant before getting any other treatments. We found out that the VGPR or better was 97%. We dont see that in the high-risk [patients with] myeloma. The MRD negativity rate was 75%. [This is also rarely] seen in high-risk [patients with] myeloma even after transplant.

The primary endpoint was very impressive for us. We waited over 2 years to show [whether] this MRD-negativity rate and the VGPR translate to better progression-free survival [PFS] and overall survival [OS]. We found out that the 2-year PFS was 83%which historically [has been] around 60% or lessand then the OS was 97%. Only 1 patient died from COVID-19 infection.

This is a new regimen, and its being used in a new era where theres many other treatments; maybe the outcomes are better because of other confounders. We looked around the same time period of 2018 to 2021, and we chose a control of high-risk [patients with] myeloma who were treated with us at MD Anderson. We looked at the data to compare our study patients to these control patients who were treated homogeneously in the same way, but without the [natural killer] cells without the elotuzumab without the lenalidomide. We found a statistically significant improvement in our study patients compared [with] the control. In the control arm, the 2-year, PFS was only 60%, and the 2-year OS was only 83%. Thats compared [with] 83% PFS in our study and 97%; it is statistically significant.

Srour SA, Mehta RS, Shah N, et al. Phase II study of umbilical cord bloodderived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). J Clin Oncol. 2022;40(suppl 16):8009-8009. doi:10.1200/JCO.2022.40.16_suppl.8009

See the original post here:
Samer A. Srour, MB, ChB, MS, Reviewed Findings of CB-NK Cells and Elotuzumab Regimen in High-Risk Multiple Myeloma - Cancer Network

Insights of Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market from 2022 to 2028, according to MarketsandResearch.biz, is a specialist and in-depth analysis of the sector with a specific focus on the Key Trends. The study aims to give readers a high-level overview and thorough segmentation by kind, end-use, application, and area. Over the projection period of 2022-2028, global growth is expected to be strong. The report looks into competing variables critical for moving your company to the next level of development.

The market rise in trends for this industry is then estimated in this study. This section also looks at upstream raw materials, downstream demand, and actual market movements. In addition, the market study examines the global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry in terms of market segmentation, regional coverage, growth factors, and market difficulties.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/166576

Emerging market players in the worldwide market:

Janssen, Qiagen, Advanced Cell Diagnostics, ApoCell, Biofluidica, Clearbridge Biomedics, CytoTrack, Celsee, Fluxion, Gilupi, Cynvenio, On-chip, YZY Bio, BioView, Fluidigm, Ikonisys, AdnaGen, IVDiagnostics, Miltenyi Biotec, ScreenCell, Silicon Biosystems,

The following are the essential product categories covered in the report:

CellSearch, Others,

The report discusses the following application types:

Breast Cancer Diagnosis and Treatment, Prostate Cancer Diagnosis and Treatment, Colorectal Cancer Diagnosis and Treatment, Lung Cancer Diagnosis and Treatment, Other Cancers Diagnosis and Treatment,

The following are the most critical nations included in the market report:

North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe), Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia), South America (Brazil, Argentina, Colombia, and Rest of South America), Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/166576/global-circulating-tumor-cells-ctcs-and-cancer-stem-cells-cscs-market-2021-by-company-regions-type-and-application-forecast-to-2026

The entire market is covered, focusing on scope, production, manufacturing value, loss/profit, supply/demand, and import/export. The market research then forecasts global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) industry growth patterns and contains strategic partnerships. This study also includes an investment feasibility analysis, a SWOT analysis, and a capital appreciation assessment.

Report Includes:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on 1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: 1-201-465-4211Email: sales@marketsandresearch.biz

See the original post:
Global Circulating Tumor Cells (CTCs) and Cancer Stem Cells (CSCs) Market Application, Trends, Growth, Opportunities and Worldwide Forecast 2022 To...

AT Piping Inverness, reporters Imogen James and Rachel Smart added themselves to the stem cell donor database in a bid to become the perfect match for an Easter Ross three-year-old.

Josie Davidson, of Alness, suffers from a rare genetic mutation and her parents are desperately seeking a match so she can undergo a bone marrow transplant.

Blood cancer charity DKMS had a stall at Piping Inverness in Bught Park yesterday and it only takes a few simple steps to potentially save a life.

First, you have to fill out a simple form with your contact information.

Next, you take two swabs and rub them against your the inside of your cheek for a minute.

Then you take the final swap and rub it in the same place again.

You have to let all three air dry for about 30 seconds, then they are packaged up by the helpful volunteers and sent away to be added to the list.

You will be contacted about a month later with your details.

The process could not be simpler.

Read more:
WATCH: How to donate your stem cells to help people in need as Easter Ross family issue fresh appeal for daughter - RossShire Journal

TheStem Cells Cryopreservation Equipments Marketreport is prepared with the sole purpose of equipping players with industry-leading analysis and useful recommendations for securing the best position in the global Stem Cells Cryopreservation Equipments market. You can discover high growth opportunities in the global Stem Cells Cryopreservation Equipments market through our exclusive research and assess risk factors to stay ready for any market issues in advance. Our deep segmentation research allows us to focus on key segments of the global Stem Cells Cryopreservation Equipments market and formulate effective strategies to capitalize on the growth prospects they have created. The report includes a study of Stem Cells Cryopreservation Equipments market sizes by value and volume and provides important market figures such as average annual,market share,growth rate,production,consumption and revenue.

The regional analysis provided in this study provides a complete study of the growth of the global Stem Cells Cryopreservation Equipments market in different regions and countries. Readers are also provided with comprehensive competitive analysis, which includes detailed profiling of leading players operating in the global Stem Cells Cryopreservation Equipments market. The report has a dedicated section on market dynamics where market influencers,Stem Cells Cryopreservation Equipments market growth drivers,limitations,challenges,trends and opportunities are extensively discussed. The statistical information provided in this report serves as a powerful tool to clearly and quickly understand the progress of the Stem Cells Cryopreservation Equipments market over the past few years and in the coming years.

Get Sample Copy (Including FULL TOC, Graphs And Tables) Of This Report @https://www.verifiedmarketreports.com/download-sample/?rid=42996

Study of Competitive Landscape

It starts with an overview of the supplier landscape followed by industry concentration analysis and ranking of the major players in the global Stem Cells Cryopreservation Equipments market. In the competitive scenario, our analysis shed light on the following topics.

LeadingStem Cells Cryopreservation Equipments Market Players are as followed:

Global Stem Cells Cryopreservation Equipments Market segmentation :

Stem Cells Cryopreservation Equipments Market Segment by Type :

Stem Cells Cryopreservation Equipments Market Segment by Application :

Get Exclusive Discount on this Premium Report @https://www.verifiedmarketreports.com/ask-for-discount/?rid=42996

Stem Cells Cryopreservation Equipments Market Report Scope

Regional market analysis Stem Cells Cryopreservation Equipments can be represented as follows:

This part of the report assesses key regional and country-level markets on the basis of market size by type and application, key players, and market forecast.

The base of geography, the world market of, Stem Cells Cryopreservation Equipments has segmented as follows:

To Gain More Insights into the Market Analysis, Browse Summary of the Research Report @https://www.verifiedmarketreports.com/product/global-stem-cells-cryopreservation-equipments-market-2019-by-manufacturers-regions-type-and-application-forecast-to-2024/

Visualize Anesthesia Delivery Systems Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Anesthesia Delivery Systems Market using VMI @https://www.verifiedmarketresearch.com/vmintelligence/

Top Trending Reports

Global Solar Cell (Photovoltaic) Equipment Market Size And Forecast

Global Stem Cells Cryopreservation Equipments Market Size And Forecast

Global Melt Pump Market Size And Forecast

Global Differential Scanning Calorimeter (DSC) Market Size And Forecast

Global Ozone Disinfection Machine Market Size And Forecast

Global Underwater Pelletizer Market Size And Forecast

Global Explosion Protection Market Size And Forecast

Global Chromatography Instruments Market Size And Forecast

Global Ditcher Market Size And Forecast

Global Navigation Satellite System (GNSS) Market Size And Forecast

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: sales@verifiedmarketreports.com

Website: https://www.verifiedmarketreports.com/

View post:
Stem Cells Cryopreservation Equipments Market Insights 2022 And Analysis By Top Keyplayers Chart, Worthington Industries, Cesca Therapeutics,...

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Cellectis (the Company) (Euronext Growth: ALCLS NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes research data on its novel immune-evasive universal CAR T-cells in Nature Communications, following an oral presentation at the American Society of Cell and Gene Therapy (ASGCT) on May 16.

Cellectis next generation of universal CAR T-cells have the potential to improve the persistence and to allow large-scale deployment of T-cell product candidates in allogeneic settings against multiple malignancies.

Universal CAR T-cell therapies are poised to revolutionize the treatment of selected hematologic malignancies. However, realizing the full potential of CAR T in an allogeneic setting requires universal CAR T-cells that can kill target tumor cells, avoid depletion by the host immune system via the host versus graft reaction (HvG), and proliferate without attacking host tissues via the graft versus host reaction (GvH).

While the prevention of GvH can be readily addressed by the inactivation of T cell receptor T (TCR) expression in a CAR T-cell, prevention of HvG remains a major challenge.

To address this challenge, the Cellectis investigators engineered CAR T-cells to be deficient in Class 1 major histocompatibility complex (MHC-1) and to express the Natural Killer (NK) inhibitor HLA-E, in order to endow them with immune-evasive properties toward alloreactive Tc ells and NK cells.

This engineering approach is very promising and could enable the universal CAR T-cells to become transiently invisible to NK and alloreactive T-cells, allowing them to eradicate tumor cells before being rejected by the patients immune system. This could enable the broad use of universal CAR T-cells in allogeneic settings, for the benefit of a wider population of patients, said Julien Valton, Ph.D., Vice President Gene Therapy at Cellectis.

One potential advantage of this approach is to spare endogenous immune effectors and allow them to work in concert with CAR T-cells in the fight against hard-to-treat cancers, including solid tumors, said Laurent Poirot, Ph.D. Senior Vice President Immuno-Oncology at Cellectis.

The research data show that:

This article is available on Nature Communications website by clicking on this link:https://www.nature.com/articles/s41467-022-30896-2

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

Cellectis headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit http://www.cellectis.com

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube

For further information, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

Investor Relation contact:

Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577

Forward-looking StatementsThis press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as anticipate, believe, intend, expect, plan, scheduled, could, would and will, or the negative of these and similar expressions. These forward-looking statements, which are based on our managements current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the potential of our research or preclinical programs. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with biopharmaceutical product candidate development. With respect to our cash runway, our operating plans, including product development plans, may change as a result of various factors, including factors currently unknown to us. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2021 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

The rest is here:
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved...

CHICAGO, June 21, 2022 /PRNewswire/ --According to the new market research report "Stem Cell Assays Market by Type (Viability, Proliferation, Differentiation, Apoptosis), Cell Type (Mesenchymal, iPSCs, HSCs, hESCs), Product & Service (Instrument), Application (Regenerative Medicine, Clinical Research), End User - Global Forecast to 2027", published by MarketsandMarkets, the global market is projected to reach USD 4.5 billion by 2027 from USD 1.9 billion in 2022, at a CAGR of 17.7 % during the forecast period of 2022 to 2027.

Browse in-depth TOC on "Stem Cell Assays Market"393 Tables 47 Figures 331 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=47610330

The stem cell assays market is expected to grow at a CAGR of 17.7% during the forecast period. The growth of the market is projected to be driven by increasing funding for stem cell research, rising demand for cell-based assays in drug discovery, and the rising incidence of cancer across the globe.

The viability/cytotoxicity assays accounted for the largest share of the type segment in the stem cell assays market in 2021.

Cell viability assays help to determine the number of live and dead cells in a culture medium. The viability/cytotoxicity assays includes various types such as tetrazolium reduction assays, resazurin cell viability assays, calcein-AM cell viability assays, and other viability/cytotoxicity assays. The segment accounted for the largest share on 2021. Increase in demand for stem cell assays in drug discovery and development is projected to drive the segment growth.

The adult stem cells segment accounted for the largest share of the cell type segment in the stem cell assays market in 2021.

The adult stem cells accounted for the largest share of the stem cell assay market. The stem cells include mesenchymal stem cells, induced pluripotent stem cells, hematopoietic stem cells, umbilical cord stem cells, and neural stem cells. Increasing demand for mesenchymal stem cells and induced pluripotent stem cells for development of stem cell based therapies and rising R&D spending are various factors projected to drive the segment growth.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=47610330

The Asia Pacific region is the fastest-growing region of the stem cell assays market in 2021.

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the stem cell assays markets of China and India is mostly driven by growing public-private funding to support stem cell product development and commercialization and rising prevalence of cancer & other diseases. Furthermore, growing emphasis on strategic initiatives (such as acquisitions, partnerships, and collaborations) by biopharma and biotech companies is expected to support the market growth in the region.

Key players in the stem cell assays market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Danaher (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), PerkinElmer (US), Agilent Technologies (US), Promega Corporation (US), Cell Biolabs (US), Miltenyi Biotec (Germany), STEMCELL Technologies (Canada), Bio-Techne Corporation (US), FUJIFILM Holdings Corporation (Japan), Charles River Laboratories (US), HemoGenix Inc. (US), Lonza Group (Switzerland), Takara Bio Inc. (Japan), Creative Bioarray (US), AAT Bioquest, Inc. (US), BPS Bioscience, Inc. (US), Enzo Biochem (US), PromoCell GmbH (Germany), Biotium (US), Geno Technology (US), Abcam plc (UK), and ReachBio Research Labs (US).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=47610330

Browse Adjacent Markets: Biotechnology Market Research Reports & Consulting

Browse Related Reports:

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) (2022 - 2026)https://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025https://www.marketsandmarkets.com/Market-Reports/regenerative-medicine-market-65442579.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: sales@marketsandmarkets.comResearch Insight: https://www.marketsandmarkets.com/ResearchInsight/stem-cell-assay-market.aspVisit Our Web Site: https://www.marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/stem-cell-assay.asp

Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg

SOURCE MarketsandMarkets

View post:
Stem Cell Assays Market worth $4.5 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire UK